20270 ⎘
Medicinal preparations containing organic active ingredients; Nitriles; Isonitriles having a ring, e.g. verapamil
Use of rasagiline for the treatment of multiple system atrophy
#1202Adenoviral vectors and methods and uses related thereto
#1203Method for administering homeopathically potentized antibody
#1204ESTER COMPOUND AND MEDICAL USE THEREOF
#1205CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS
#1206METHOD FOR TREATING PULMONARY ARTERIAL HYPERTENSION
#1207Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
#1208Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
#1209cAMP DEPENDENT INDUCTION OF AUTOPHAGY
#1210Molecular Targets for Treatment of Learning and Memory Dysfunction
#1211Isoform of bruton's tyrosine kinase (BTK) protein
#1212Compounds for treating proliferative disorders
#12134-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
#1214Combination of HMG-COA Reductase Inhibitors with Phosphodiesterase 4 Inhibitors for the Treatment of Inflammatory Pulmonary Disease
#1215CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA
#1216COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS
#1217COMPOUNDS ACTING ON THE SEROTONIN TRANSPORTER
#1218COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS
#1219COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS
#1220Ternary Pesticidal Mixtures
#1221Methods for treating retroviral infections
#1222Solid forms of selective androgen receptor modulators
#1223Pesticidal mixtures
#1224Metabolites of selective androgen receptor modulators and methods of use thereof
#1225Synthetic triterpenoids and methods of use in the treatment of disease
#1226FORMULATIONS FOR CATHEPSIN K INHIBITORS
#1227ABUSE RESISTANT MELT EXTRUDED FORMULATION HAVING REDUCED ALCOHOL INTERACTION
#1228Pharmaceutical composition
#1229Modulators of ATP-binding cassette transporters
#1230NANOPARTICULATE BICALUTAMIDE FORMULATIONS
#1231JAK/STAT pathway inhibitors and uses thereof
#1232BCRP/ABCG2 inhibitor
#1233Modulators of ATP-binding cassette transporters
#1234METHODS FOR USING MODULATORS OF PROLINE-RICH TYROSINE KINASE 2
#1235Protein kinase C as a target for the treatment of respiratory syncytial virus
#1236Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
#1237PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS
#1238-disubstituted aminoalkylbiphenyl antagonists of prostaglandin Dreceptors
#1239COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS
#1240Ion-Channel Regulator Compositions and Methods of Using Same
#1241Organic Compounds
#1242Compositions and methods for treatment of diabetic retinopathy
#1243Treating renal cancer using a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde
#1244Treatments for Viral Infections
#1245COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS
#1246COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS
#1247Mast cell stabilizers in the treatment of obesity
#1248COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS
#1249Sustained release dosage form
#1250Novel Pharmaceutical
#1251COMPOSITIONS AND METHODS HAVING MT1 RECEPTOR ACTIVITY
#1252Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders
#1253TREATMENT OF SYMPTOMS OF MOTOR DYSFUNCTION
#1254Amino acid derivatives as calcium channel blockers
#1255PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION
#1256Cathepsin K Inhibitors and Obesity
#1257CRUSH RESISTAN DELAYED-RELEASE DOSAGE FORM
#1258Pyridoxal-5-Phosphate and Related Compounds in Combination With Therapeutic Cardiovascular Compounds for Treating Angina
#1259Method For Treating Huntington's Disease by Inhibiting Dephosphorylation of Huntingtin at S421
#1260Method of Treating Cellular Damage
#1261Compositions and Methods Relating to Mitochondrial Hyperpolarization in Neurological Disease
#1262Composition for inhibition of cathepsin K
#1263Protein kinase C as a target for the treatment of respiratory syncytial virus
#1264Therapeutic compositions and methods of use
#1265MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES
#1266Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
#1267DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION
#1268ANTIVIRAL INHIBITION OF CAPSID PROTEINS
#1269Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
#1270Therapeutic compounds and methods of use
#1271Paclitaxel enhancer compounds
#1272Combination Comprising Zd6474 And An Antiandrogen
#1273Treatment of cancer by a combination of non-ionizing radiation and androgen deprivation
#1274Oral Dosage Form
#1275Methods of treating gastrointestinary and genitourinary pain disorders
#1276Means and Methods For Treating a Disease Which is Associated With an Excess Transport of Hyaluronan Across a Lipid Bilayer
#1277Combinations comprising antimuscarinic agents and beta-adrenergic agonists
#1278Tablets comprising entacapone and crospovidone
#1279COMPOUNDS WITH ANTI-ANDROGENIC ACTIVITY AND THE USE THEREOF
#1280Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
#1281Method of treating a pathological syndrome and a pharmaceutical agent
#1282Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
#12834-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
#1284Pharmaceutical Composition
#1285Modulators of ATP-binding cassette transporters
#1286Androgen Receptor Modulators
#1287Combinations Comprising Antimuscarinic Agents and Corticosteroids
#1288Method of treating a pathological syndrome and a pharmaceutical agent
#1289Method of treating a pathological syndrome and a pharmaceutical agent
#1290Methods for treating at least one condition having MT1 receptor, 5HT2B receptor, and L-type calcium channel activity
#1291Combinations Comprising Antimuscarinic Agents and Beta-Adrenergic Agonists
#1292Composition for accelerating bone fracture healing
#1293Method of treating a pathological syndrome and a pharmaceutical agent
#1294Method of treating a pathological syndrome and a pharmaceutical agent
#1295Pharmaceutical Compositions Comprising Droxidopa
#1296Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
#1297Supportive treatment of liver disease
#1298Therapeutic And/Or Preventive Agents For Chronic Skin Diseases
#1299Selective androgen receptor modulators for treating diabetes
#1300Tolerance to Graft Prior to Thymic Reactivation
#1301Combination therapy for the treatment and improvement of scars
#1302Method of treating a condition associated with phosphorylation of TASK-1
#1303Solid dosage formulations
#1304Combinations Comprising Antimuscarinic Agents and Pde4 Inhibitors
#1305Aryl aniline βadrenergic receptor agonists
#1306Method of treating a pathological syndrome and a pharmaceutical agent
#1307Compositions and Methods Relating to Pyrimidine Synthesis Inhibitors
#1308Methods for reducing platelet activation and for the treatment of thrombotic events
#1309Dosage Form for Time-Varying Patterns of Drug Delivery
#1310USE OF (Z)-2-CYANO-3-HYDROXY-BUT-2-ENOIC ACID-(4'-TRIFLUOROMETHYLPHENYL)-AMIDE FOR TREATING INFLAMMATORY BOWEL DISEASE
#1311Inhibitors of anthrax lethal factor
#1312Remedy for urinary tract diseases
#1313Combination comprising antimuscarinic agents and PDE4 inhibitors
#1314Agent for treating chronic pelvic pain syndrome
#1315Selective androgen receptor modulators for treating muscle wasting
#1316Calcilytic compounds
#1317Treatment of cancer by a combination of non-ionizing radiation and androgen deprivation
#1318Composition for regenerative treatment of cartilage disease
#1319Water-soluble stabilized self-assembled polyelectrolytes
#1320Substituted sulfonamides
#1321Methods and compositions for reducing skin damage
#1322Cathepsin cysteine protease inhibitors
#1323Bis(thio-hydrazide amide) formulation
#1324Method of treating a condition associated with phosphorylation of task-1
#1325Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
#1326Therapeutic curcumin derivatives
#1327Methods of modulating intestinal fluid balance
#1328Inhibition of STAT3 signal transduction for human cancer therapy
#1329Method of inhibiting remnant lipoprotein production
#1330Anti-inflammatory activity of phenethylisothiocyanate (PEITC) and the seed preparation containing this compound
#1331Treatment of actinic keratoses with calcium channel blockers
#1332Inhibition of olfactory neurosensory function to treat eating disorders and obesity
#1333Direct drug delivery system based on thermally responsive biopolymers
#1334Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
#1335Proteasome inhibitors and uses thereof
#1336Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
#1337Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
#1338Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
#1339Methods of decreasing calcification
#1340Method for treating osteoarthritis
#1341Therapeutic modulation of PPARgamma activity
#1342Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
#1343Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
#1344Methods for treatment of multiple sclerosis
#1345(2-carboxamido)(3-amino)thiophene compounds
#1346Selective androgen receptor modulators and methods of use thereof
#1347Inhibition of vascular endothelial growth factor
#1348Treatments for viral infections
#1349Use of nf-kappa b inhibitors for the treatment of mastitis
#1350Selective androgen receptor modulators and methods of use thereof
#1351Use
#1352Use of estrogen receptor-beta selective agonists for radiation-or chemotherapy-induced mucositis and radiation cystitis
#1353Combinations comprising antimuscarinic agents and corticosteroids
#1354Methods of using derivatives of (-)-venlafaxine
#1355Salts of (-)-O-desmethylvenlafaxine
#1356Crush resistant delayed-release dosage forms
#1357Combinations comprising antimuscarinic agents and beta-adrenergic agonists
#1358Combination of gh secret agogues and pde4 inhibitors for the treatment of alzheimers disease
#1359BTK inhibitors
#1360Substituted aniline derivatives
#1361Nanoparticulate bicalutamide formulations
#1362Combinations comprising antimuscarinic agents and PDE4 inhibitors
#1363Bis(thio-hydrazide amides) for increasing Hsp70 expression
#1364Novel signaling pathway for the production of inglammatory pain and neuropathy
#1365Breast cancer resistance protein () inhibitor
#1366Paclitaxel enhancer compounds
#1367Treating wasting disorders with selective androgen receptor modulators
#1368Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
#1369Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators
#1370Bicalutamide polymorphs
#1371Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
#1372Modulators of ATP-binding cassette transporters
#1373Method for reducing exacerbations associated with COPD
#1374Therapeutic diphenyl ether ligands
#1375Severe sepsis preventive therapeutic agent
#1376Use of phosphodiesterase-4 inhibitors as enhancers of cognition
#1377Selective androgen receptor modulators and methods of use thereof
#1378Remedies for neurodegenerative diseases
#1379Calcilytic compounds
#1380Method and compositions for treating pulmonary diseases
#1381Palatable suspending vehicle for pharmaceutical ingredients
#1382Use of estrogen related receptor-modulating aryl ethers
#1383Methods of inhibiting tumor cell proliferation
#1384Tricyclic inhibitors of poly(ADP-ribose) polymerases
#1385Therapeutic compounds and methods of use
#1386Combination therapy wherein a serotonin reuptake inhibitor is used
#1387Combinations comprising antimuscarinic agents and corticosteroids
#1388Compositions and method for treating infection in cattle and swine
#1389Thrombopoetin receptor activator and process for producing the same
#1390Compounds for treatment of cell proliferative diseases
#1391Serine protease inhibitors
#1392Combinations comprising antimuscarinic agents and PDE4 inhibitors
#1393Combinations comprising antimuscarinic agents and beta-adrenergic agonists
#1394Use of ER selective NF-kB inhibitors for the treatment of sepsis
#1395Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors
#1396Therapeutic modulation of PPARgamma activity
#1397Water-soluble stabilized self-assembled polyelectrolytes
#1398Modified-release compositions of at least one form of venlafaxine
#1399Methods for treating retroviral infections
#1400Compositions and methods for modulating interaction between polypeptides
#1401N-aryloxypropanolyl-N′-phenethyl-urea
#1402Methods of treatment using an EP2 selective receptor agonist
#1403Antiparasitic composition
#1404(2-Carboxamido)(3-amino)thiophene compounds
#1405Multiparticulate O-desmethylvenlafaxine salts and uses thereof
#1406Osmotic device containing a venlafaxine salt and a salt having an ion in common
#1407JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
#1408Novel external agent
#1409Methods of inducing ovulation using a non-polypeptide camp level modulator
#1410Methods of indirectly stimulating the vagus nerve with an electrical field
#1411HIV protease inhibiting compounds
#14124-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
#1413Oxamide inhibitors of plasminogen activator inhibitor-1
#1414Compositions and methods for inhibiting NF-κB mediated tumorigenicity and adhesion dependent survival of cancer cells
#1415Il-6 production inhibitors
#1416Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
#1417Cell line comprising vector encoding truncated FLK-1 receptor
#1418Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
#1419Tricyclic inhibitors of poly(ADP-ribose) polymerases
#1420Haloacetamide and azide substituted compounds and methods of use thereof
#1421Pharmaceuticals for the treatment of rejection reactions in organ transplantations
#1422Ester compound and medicinal use thereof
#1423Compositions comprising inhibitors of IMPDH enzyme
#1424Methods for using modulators of proline-rich tyrosine kinase 2
#1425Materials and methods for the treatment of depression
#1426Use of propionyl-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease
#1427Calcilytic compounds
#1428Combination drug therapy for treating hypertension
#1429Methods of inhibiting tumor cell proliferation
#1430Cancer remedy comprising anthranilic acid derivatives as active ingredient
#1431Bicalutamide polymorphs
#1432Composition and method for treating erectile dysfunction and reducing fibrosis in erectile tissue of the human penis
#1433Treatment of Th2 dominated immunological disease states with progesterone receptor antagonists
#1434Styryl acrylonitrile compounds and their use to promote myelopoiesis
#1435Taxol enhancer compounds
#1436Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
#1437Bicalutamide compositions
#1438Pharmaceutical compositions comprising aryl-substituted acyclic enediyne compounds
#1439Compositions and methods for treatment of peri-implantitis and periodontitis
#1440Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of Parkinson's disease
#1441Biocompatible resin composition and method of manufacturing dissolvable microneedles for transdermal delivery using biocompatible resin
#1442Non-surgical laser treatment for a fibrous mass
#1443Non-surgical laser treatment for a fibrous mass
#1444Non-surgical laser treatment for a fibrous mass